| Assessment Status | Rapid Review complete |
| HTA ID | - |
| Drug | Ceftazidime/avibactam |
| Brand | Zavicefta® |
| Indication | For the treatment of CIAI, cUTI, HAP (including VAP) and gram negative infections due to aerobic Gram-negative organisms in adult patients with limited treatment options. |
| Assessment Process | |
| Rapid review commissioned | 17/05/2017 |
| Rapid review completed | 13/06/2017 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended at the Submitted Price |
The HSE has approved reimbursement following confidential price negotiations November 2017.
